newsfilter
← Latest News
GlobeNewswire·

Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update

~ Reports KEVEYIS® (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~ ~ Strongbridge Remains On-Track to Meet, or Potentially Exceed, the Top